Journals / İnönü Üniversitesi Turgut Özal Tıp Merkezi Dergisi / 2015 / Cilt: 22 - Sayı: 1

Özofagus Varis Kanamalarına Güncel Yaklaşımlar

Current Approaches to Esophageal Variceal Bleeding

Pages
56–65
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, we aimed to evaluate the current approaches to esophageal variceal bleeding.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Esophageal varices are collateral veins at the distal esophagus between gastric and azygos veins arising following increased portal pressure.
📊
Key Findings & Data:Vein pressure above 10 mmHg is regarded as portal hypertension, in which portal vein-hepatic vein pressure gradient is increased.
💡
Conclusion & Impact:In this study, we aimed to evaluate the current approaches to esophageal variceal bleeding.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Esophageal varices are collateral veins at the distal esophagus between gastric and azygos veins arising following increased portal pressure. Vein pressure above 10 mmHg is regarded as portal hypertension, in which portal vein-hepatic vein pressure gradient is increased. This status is seen as "clinically important portal hypertension" and it is most common in liver cirrhosis. Acid and esophageal variceal bleeding is the result of portal hypertension, which are the signs of advanced disease with poorer survival rates. Esophageal varices develop in 30% of the patients with compensated cirrhosis and 60-70% of the patients with decompensated cirrhosis. Varice development incidence is around 4-12% in cirrhotic patients without varices. Esophageal variceal hemorrhage has high recurrence, mortality, and morbidity rates requiring immediate medical treatment and these constitute approximately 10% of upper gastrointestinal bleeding, which is one of the major causes of mortality in patients with cirrhosis. Bleeding develops in 30% of the cirrhotic patients with esophageal varices diagnosed during endoscopy. The mortality of the first bleeding episode ranges from 25 to 70% and after the first bleeding episode rebleeding occurs at a rate of 75-80% in six to twelve months. Variceal diameter, grade, degree of red dots, and cirrhosis are among the factors that increase the risk of variceal bleeding. The risk of bleeding in Grade 1 varices is 8% and a higher grade increases the risk of bleeding four to five folds. Pharmacological endoscopic and antibiotic treatment constitutes the basis for esophageal variceal bleeding treatment. In this study, we aimed to evaluate the current approaches to esophageal variceal bleeding.

Özet

ofagus varisleri portal kan basıncının artmasına bağlı, özofagusun distalinde gastrik venler ile azigos ven arasında geşilen kolaterallerdir. Portal ven basıncının 10 mm Hg'nin üzerinde olmasına portal hipertansiyon denilir. Portal hipertansiyonda portal ven - hepatik ven basınç gradiyenti artmıştır. Bu durum "klinik olarak önem arz eden portal hipertansiyon" olarak adlandırılmaktadır ve en sık karaciğer sirozunda karşılaşılır. Karaciğer sirozu olan hastalarda asit oluşumu ve özofagus varis kanamalarının olması ilerlemiş hastalık belirtileridir ve bu hastaların beklenen yaşama süresi oldukça kısalmıştır. Kompanze sirozlu hastaların %30'unda dekompanze sirozlu hastaların %60-70'inde özofagus varisi gelişmektedir. Varisi olmayan sirotik hastalarda yıllık varis oluşum hızı %4-12 dolayındadır. Özofagus varis kanaması yüksek rekürrens, mortalite ve morbidite oranına sahip acil medikal tedavi gerektiren hastalıklardan biridir. Özofagus varis kanamaları üst gastrointestinal sistem kanamalarının yaklaşık %10'unu oluştururlar ve sirozlu hastalarda başlıca mortalite nedenlerindendir. Özofagus varis kanaması, endoskopik olarak özofagus varisi saptanan sirotik hastaların %30'unda gelişmektedir. İlk kanama epizodunun mortalitesi % 25-70 arasında değişmektedir ve ilk kanama sonrası varislerin % 75-80'inde altı ay ya da bir yıl içinde yeniden kanama meydana gelir. Varis çapı, grade, kırmızı noktalanmalar ve siroz derecesi varis kanaması riskini arttıran faktörlerdir. Grade 1 varislerde kanama riski %8 iken grade arttıkça kanama riski 4-5 kat artmaktadır. Özofagus varis kanamalarında tedavinin temelini farmakolojik, endoskopik ve antibiyotik tedavisi oluşturur. Bu çalışmada özofagus varis kanamalarına güncel yaklaşımlar ele alınmıştır.

🔖

Cite This Article

OTAN, E., YILMAZ, S., PİŞKİN, T., KULTUTÜRK, K., ÜNAL, B., AYDIN, C. (2022). Özofagus Varis Kanamalarına Güncel Yaklaşımlar. İnönü Üniversitesi Turgut Özal Tıp Merkezi Dergisi, Cilt: 22 - Sayı: 1, 56–65. https://ajindex.com/articles/549299

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Nina D, Frédéric O, Paul C. Current management of the complications of portal hypertension: variceal bleeding and ascites 2006;174:1433-43
  2. Shibayama Y, Nakata K. Localization of increased hepatic vascular resistance in liver cirrhosis. Hepatology 1985;5:643- 8
  3. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002;35:478-91
  4. Bosch J, Mastai R, Kravetz D, Navasa M, Rodes J. Hemodynamic evaluation of the patient with portal hypertension. Semin Liver Dis 1986; 6: 309-17
  5. Lee SS, Hadengue A, Moreau R, Sayegh R, Hillon P, Lebrec D. Postprandial hemodynamic responses in patients with cirrhosis. Hepatology 1988;8:647-51
  6. Garcia-Pagan JC, Santos C, Barbera JA, Luca A, Roca J, Rodriguez-Roisin R, et al. Physical exercise increases portalpressure in patients with cirrhosis and portal hypertension. Gastroenterology 1996;111:1300-6
  7. Ioannou GN, Doust J, Rockey DC. Systematic review: terlipressin in acute oesophageal variceal haemorrhage. Aliment Pharmacol Ther 2003;17:53-64
  8. Bosch J, Dell'era A. Vasoactive drugs for the treatment of bleeding esophageal varices. Gastroenterol Clin Biol 2004;28 Spec No 2:B186-9
  9. Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin.Gastroenterology 1981;80:518-25
  10. Moller S, Brinch K, Henriksen JH, Becker U. Effect of octreotide on systemic, central,and splanchnic haemodynamics in cirrhosis. J Hepatol 1997;26:1026-33
  11. Group IOVS, Burroughs AK. Double blind RCT of 5-day octreotide versus placebo, associated with sclerotherapy for trial/failures [abstract]. Hepatology 1996;24:352A
  12. Calès P, Masliah C, Bernard B, Garnier PP, Silvain C, Szostak-Talbodec N, et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. French Club for the Study of Portal Hypertension. N Engl J Med 2001;344:23-8
  13. Bureau C, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C, Perreault P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004;126:469-75
  14. Duggan JM. Review article: transfusion in gastrointestinal haemorrhage -- If, when and how much? Aliment Pharmacol Ther 2001;15:1109-13
  15. Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control